Tolero Pharmaceuticals Presents Positive Preclinical Data on Programs in Leukemia and Anemia at the 56th ASH Annual Meeting and Exposition

SALT LAKE CITY, Utah - November 13, 2014 - Tolero Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing treatments for oncology and hematologic diseases, announced today that it will present two oral and two poster presentations at the 56th American Society of Hematology (ASH) Annual Meeting in San Francisco, California, December 6-9, 2014. The presentations include preclinical proof-of-concept of Tolero’s Axl kinase inhibitors for the treatment of leukemias and ALK2 inhibitors, which regulate hepcidin, for the treatment of anemia.

Details of the oral presentations are as follows:

**Abstract:** #212  
**Title:** Novel Series of ALK2 Inhibitors That Alter Hepcidin Expression As Potential Therapeutics for Anemia of Chronic Disease  
**Presenter:** Steven L. Warner, PhD  
**Session Title:** 102. Regulation of Iron Metabolism: Iron-restrictive Anemias - New Pathways and Therapeutic Strategies  
**Date:** Monday, December 8, 2014, 7:15 AM PT  
**Location:** Yerba Buena Ballroom Salon 9 (San Francisco Marriott Marquis)

**Abstract:** #831  
**Title:** Axl Regulates Fibroblast Growth Factor Receptor Signaling in B-Cell Chronic Lymphocytic Leukemia: Dual Targeting in CLL Therapy  
**Presenter:** Sutapa Sinha  
**Session Title:** 641. CLL: Biology and Pathophysiology, excluding Therapy: Novel Prognosticators and Therapeutic Targets  
**Date:** Tuesday, December 9, 2014, 8:00 AM PT  
**Location:** South Building, Esplanade 302 (Moscone Center)

Details of the poster presentations are as follows:

**Abstract:** #1946  
**Title:** Targeted Inhibition of Axl Primes Chronic Lymphocytic Leukemia B-Cells for Apoptosis: Synergistic/Additive Effects in Combination with Bruton’s Tyrosine Kinase Inhibitors  
**Presenter:** Sutapa Sinha  
**Session Title:** 641. CLL: Biology and Pathophysiology, excluding Therapy: Poster I  
**Date:** Saturday, December 6, 2014, 5:30 PM-7:30 PM PT  
**Location:** West Building, Level 1 (Moscone Center)
Abstract: #2350
Title: The Receptor Tyrosine Kinase Axl Is Required for Resistance to FLT3-Targeted Therapy in Acute Myeloid Leukemia
Presenter: Il-Kyoo Park
Session Title: 617. Acute Myeloid Leukemia: Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis: Poster II
Date: Sunday, December 7, 2014, 6:00 PM-8:00 PM PT
Location: North Building, Hall E (Moscone Center)

About Tolero
Tolero Pharmaceuticals is a clinical stage biopharmaceutical company developing treatments to improve and extend the lives of patients with serious oncological and hematological diseases. Our diverse pipeline targets important biological drivers of blood disorders to treat leukemias and anemia as well as important targets of drug resistance and transcriptional control.

Contact:
Joe Nilson
Tolero Pharmaceuticals, Inc.
801-285-6003
bizdev@toleropharma.com